Governor Josh Shapiro and GSK leadership announced that the global biopharmaceutical company will make a major investment of up to $800 million in Pennsylvania, expanding its research and development (R&D) and manufacturing footprint at an existing facility in Lancaster County. . The Commonwealth is supporting the expansion with a $21 million investment, which will create at least 200 new high-paying jobs. This is the largest federally supported economic development project in Lancaster County history.
GSK will expand its existing facility at 325 North Bridge Street in Marietta to include a new facility to manufacture vaccines and pharmaceuticals. One in four Americans has now received the vaccine supplied by the company’s Marietta location. This expansion will double the size and capacity of your site.
“Pennsylvania is a leader in life sciences, and GSK’s decision to make the largest single investment ever in U.S. manufacturing here in the commonwealth is a sign that Pennsylvania is one of the nation’s leaders in business growth and economic development. “It’s further proof that we’re a great state,” Shapiro said. “Our commonwealth provides the skilled workforce, market access, and innovation infrastructure that biotech and life sciences companies need to grow. The administration will continue to work with companies like GSK to drive innovation and create jobs and economic opportunities for people across the Commonwealth.”
The Department of Community and Economic Development (DCED) has supported GSK’s expansion with a comprehensive funding proposal. This includes an $18 million Redevelopment Assistance Capital Program (RACP) grant, a $2.35 million Pennsylvania First grant, and a $645,000 WEDnet grant for workforce training. GSK is also encouraged to apply for DCED’s Qualified Manufacturing Innovation and Reinvestment Credit (QMIRD) and Manufacturing Tax Credit (MTC) programs. In addition to the expansion, GSK will maintain at least 4,622 jobs across the state and maintain its U.S. headquarters in Philadelphia.
“Today, we celebrate GSK’s decision to expand here in Pennsylvania. This expansion represents one of the largest life sciences investments in the Commonwealth’s history,” said DCED Secretary Rick Siger. Ta. “Life sciences is one of the key industries we are focusing on in the Governor’s 10-year economic development strategy. There are nearly 3,100 life science companies in the Commonwealth, and under Governor Shapiro’s leadership, the industry We will continue to make bold investments like this to further revitalize Pennsylvania and create more opportunities for Pennsylvanians.”
GSK is a global biopharmaceutical company dedicated to the prevention of disease by integrating science, technology and people. The company’s U.S. headquarters are in Philadelphia, and its global headquarters are in London, England.
“This groundbreaking investment will establish Marietta as an innovation and manufacturing hub that can deliver the next generation of medicines and vaccines to people around the world,” said Regis Simard, President of Global Supply Chain at GSK. said. “We are grateful for the support of local and state officials who made this project possible, and we are excited to expand on the important work already underway at the Marietta site.”
“Marietta, Pennsylvania, first appeared on the front lines of vaccine production more than 140 years ago when the Lancaster County Vaccine Farm supplied the nation with lifesaving smallpox vaccine,” said Ezra Rothman, president of EDC Lancaster County. said. “Today, with this major investment by GSK, Lancaster County will be at the heart of the company’s North American operations for the foreseeable future. We really appreciate the local support we have received from the Donegal School District and Lancaster County.”
